PTC Therapeutics (NASDAQ:PTCT) : Traders are bullish on PTC Therapeutics (NASDAQ:PTCT) as it has outperformed the S&P 500 by a wide margin of 2.35% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 3.98%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 5.31% in the last 1 week, and is up 4.01% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The company shares have dropped -84.19% from its 1 Year high price. On Jul 20, 2015, the shares registered one year high at $62.15 and the one year low was seen on Mar 16, 2016. The 50-Day Moving Average price is $7.40 and the 200 Day Moving Average price is recorded at $13.09.
The stock has recorded a 20-day Moving Average of 7.89% and the 50-Day Moving Average is 2.59%.
PTC Therapeutics (NASDAQ:PTCT): stock turned positive on Friday. Though the stock opened at $7.51, the bulls momentum made the stock top out at $7.57 level for the day. The stock recorded a low of $7.22 and closed the trading day at $7.53, in the green by 0.27%. The total traded volume for the day was 781,974. The stock had closed at $7.51 in the previous days trading.
In an insider trading activity, Rothera Mark, officer (Chief Commercial Officer) of Ptc Therapeutics, Inc., executed a transaction worth $12,460 on March 3, 2016. A total of 2,000 shares were purchased at an average price of $6.23. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
PTC Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule therapeutics that target post-transcriptional control processes. The Companys internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. The Companys lead product, Translarna (ataluren), is used for the treatment of genetic disorders due to a nonsense mutation in ambulatory patients aged five years and older. Ataluren is in clinical development for the treatment of Duchenne muscular dystrophy caused by a nonsense mutation (nmDMD) and cystic fibrosis caused by a nonsense mutation (nmCF).